Valneva to present on chikungunya at several leading scientific conferences

Saint-herblain (france), october 21, 2024 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, announces today that members of its senior leadership team will present datasets on the world's first and only approved chikungunya vaccine, ixchiq®, at several leading scientific conferences during the fourth quarter of 2024.
VALN Ratings Summary
VALN Quant Ranking